Eloxx Pharmaceuticals (ELOX) Competitors

$0.12 -0.06 (-33.24%)

As of 03:55 PM Eastern

ELOX vs. ADIL, TRIB, SLXN, CANF, and ORGS

Should you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Adial Pharmaceuticals (ADIL), Trinity Biotech (TRIB), Silexion Therapeutics (SLXN), Can-Fite BioPharma (CANF), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.

How does Eloxx Pharmaceuticals compare to Adial Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

: Eloxx Pharmaceuticals has a beta of -1907.33, suggesting that its share price is 190,833% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
: Eloxx Pharmaceuticals' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals N/A N/A N/A
Adial Pharmaceuticals N/A -182.34% -141.27%
: In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Eloxx Pharmaceuticals Neutral
Adial Pharmaceuticals Neutral
: Adial Pharmaceuticals has a consensus price target of $22.75, indicating a potential upside of 1,321.88%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Eloxx Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eloxx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Adial Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals N/A N/A -$36.06M -$6.15 N/A
Adial Pharmaceuticals N/A N/A -$7.98M -$18.75 N/A

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-182.34%	-141.27%

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Adial Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$36.06M	-$6.15	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$18.75	N/A

Summary

Adial Pharmaceuticals beats Eloxx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Trinity Biotech?

Trinity Biotech (NASDAQ:TRIB) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
Eloxx Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Eloxx Pharmaceuticals has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trinity Biotech $43.78M 0.05 -$37.38M -$9.40 N/A
Eloxx Pharmaceuticals N/A N/A -$36.06M -$6.15 N/A
: 79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Trinity Biotech had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for Eloxx Pharmaceuticals. Trinity Biotech's average media sentiment score of 0.67 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media.
Company Overall Sentiment
Trinity Biotech Positive
Eloxx Pharmaceuticals Neutral
: Eloxx Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%.
Company Net Margins Return on Equity Return on Assets
Trinity Biotech -85.36% N/A -36.62%
Eloxx Pharmaceuticals N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.05	-$37.38M	-$9.40	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$36.06M	-$6.15	N/A

Company	Overall Sentiment
Trinity Biotech	Positive
Eloxx Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-85.36%	N/A	-36.62%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Summary

Eloxx Pharmaceuticals beats Trinity Biotech on 6 of the 11 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Silexion Therapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

: Silexion Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, suggesting that its stock price is 190,833% less volatile than the S&P 500.
: 11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 5.0% of Silexion Therapeutics shares are held by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Silexion Therapeutics had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 1 mentions for Silexion Therapeutics and 0 mentions for Eloxx Pharmaceuticals. Silexion Therapeutics' average media sentiment score of 0.84 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Silexion Therapeutics Positive
Eloxx Pharmaceuticals Neutral
: Eloxx Pharmaceuticals' return on equity of 0.00% beat Silexion Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Silexion Therapeutics N/A -387.82% -144.68%
Eloxx Pharmaceuticals N/A N/A N/A
: Silexion Therapeutics is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silexion Therapeutics N/A N/A -$11.91M -$11.10 N/A
Eloxx Pharmaceuticals N/A N/A -$36.06M -$6.15 N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silexion Therapeutics
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Eloxx Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Silexion Therapeutics	Positive
Eloxx Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-387.82%	-144.68%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$11.10	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$36.06M	-$6.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Silexion Therapeutics beats Eloxx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

: Can-Fite BioPharma has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, indicating that its stock price is 190,833% less volatile than the S&P 500.
: 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Can-Fite BioPharma had 2 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for Eloxx Pharmaceuticals. Can-Fite BioPharma's average media sentiment score of 0.34 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the media.
Company Overall Sentiment
Can-Fite BioPharma Neutral
Eloxx Pharmaceuticals Neutral
: Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharma N/A N/A N/A
Eloxx Pharmaceuticals N/A N/A N/A
: Can-Fite BioPharma has higher revenue and earnings than Eloxx Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Can-Fite BioPharma $405K 5.66 -$7.63M -$35.80 N/A
Eloxx Pharmaceuticals N/A N/A -$36.06M -$6.15 N/A
: Can-Fite BioPharma presently has a consensus price target of $65.00, indicating a potential upside of 1,757.14%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Eloxx Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.33
Eloxx Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Eloxx Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Eloxx Pharmaceuticals	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.66	-$7.63M	-$35.80	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$36.06M	-$6.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Can-Fite BioPharma beats Eloxx Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

: Orgenesis has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, suggesting that its share price is 190,833% less volatile than the S&P 500.
: 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Eloxx Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Orgenesis Neutral
Eloxx Pharmaceuticals Neutral
: Eloxx Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.
Company Net Margins Return on Equity Return on Assets
Orgenesis -3,827.81% N/A -130.18%
Eloxx Pharmaceuticals N/A N/A N/A
: Eloxx Pharmaceuticals has lower revenue, but higher earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A
Eloxx Pharmaceuticals N/A N/A -$36.06M -$6.15 N/A

Company	Overall Sentiment
Orgenesis	Neutral
Eloxx Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$36.06M	-$6.15	N/A

Summary

Eloxx Pharmaceuticals beats Orgenesis on 6 of the 9 factors compared between the two stocks.

Get Eloxx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELOX vs. The Competition

Export

Metric	Eloxx Pharmaceuticals	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$609K	$328.15M	$6.25B	$11.87B
Dividend Yield	N/A	N/A	2.73%	5.21%
P/E Ratio	-0.02	N/A	29.04	28.48
Price / Sales	N/A	189.48	476.48	60.89
Price / Cash	N/A	22.44	27.62	36.52
Price / Book	N/A	4.73	9.67	6.67
Net Income	-$36.06M	-$132.96M	$3.55B	$332.64M
7 Day Performance	0.08%	6.97%	1.70%	2.01%
1 Month Performance	-7.62%	4.03%	5.62%	9.19%
1 Year Performance	N/A	37.44%	34.42%	39.59%

Eloxx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELOX Eloxx Pharmaceuticals	N/A	$0.12 -33.2%	N/A	N/A	$609K	N/A	N/A	30	Gap Down
ADIL Adial Pharmaceuticals	2.0981 of 5 stars	$1.54 -0.6%	$22.75 +1,377.3%	N/A	$2.21M	N/A	N/A	20
TRIB Trinity Biotech	0.3528 of 5 stars	$0.60 flat	N/A	N/A	$2.16M	$49.41M	N/A	480	Positive News High Trading Volume
SLXN Silexion Therapeutics	1.1701 of 5 stars	$0.61 -3.0%	N/A	N/A	$2.10M	N/A	N/A	N/A	Positive News Upcoming Earnings
CANF Can-Fite BioPharma	1.7089 of 5 stars	$3.19 +6.7%	$65.00 +1,937.6%	N/A	$2.09M	$405K	N/A	8	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELOX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. ADIL, TRIB, SLXN, CANF, and ORGS

How does Eloxx Pharmaceuticals compare to Adial Pharmaceuticals?

Summary

How does Eloxx Pharmaceuticals compare to Trinity Biotech?

Summary

How does Eloxx Pharmaceuticals compare to Silexion Therapeutics?

Summary

How does Eloxx Pharmaceuticals compare to Can-Fite BioPharma?

Summary

How does Eloxx Pharmaceuticals compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. ADIL, TRIB, SLXN, CANF, and ORGS

How does Eloxx Pharmaceuticals compare to Adial Pharmaceuticals?

Summary

How does Eloxx Pharmaceuticals compare to Trinity Biotech?

Summary

How does Eloxx Pharmaceuticals compare to Silexion Therapeutics?

Summary

How does Eloxx Pharmaceuticals compare to Can-Fite BioPharma?

Summary

How does Eloxx Pharmaceuticals compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools